for educational and safety purposes
Every compound in the sci-wiki that affects leydig cells; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
2 sourced · 1 reference
FOX-04-DRI is one of the most elegantly targeted ideas in longevity science, a peptide senolytic engineered to seek out and clear senescent "zombie" cells while sparing healthy ones. It works by breaking the FOXO4-p53 grip that keeps worn-out cells alive and inflammatory, freeing them to self-destruct. In aged animals this has produced genuine signs of rejuvenation, from restored vitality to recovered testosterone, making FOX-04-DRI a captivating frontier tool for anyone following the biology of aging.
N163-166 (MOD6) is an orally active peptide engineered to switch the body's own testosterone production back on at its source. It targets VDAC1, a mitochondrial gatekeeper that governs the rate-limiting step of steroid synthesis, prompting the Leydig cells of the testes to make more testosterone rather than supplying an outside hormone. In male rats, VDAC1-derived oral peptides raised circulating testosterone specifically through the natural gonadal axis, and stabilizing modifications let this small peptide survive oral dosing [1]. It is an investigational research compound.
ACE-167 is an orally available synthetic tetrapeptide under preclinical development by Acesis BioMed as a non-steroidal approach to stimulating the body's own testosterone production, primarily for male hypogonadism and related conditions [company disclosures]. Rather than acting on the central nervous system, it works at the mitochondrial level within testicular Leydig cells to promote endogenous steroidogenesis. Independent peer-reviewed literature on ACE-167 is currently absent, so its profile rests on company and industry-database sources and should be regarded as preliminary.